Home › Upcoming votes › Tenaya Therapeutics, Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Tenaya Therapeutics, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | APPROVAL OF THE REVERSE STOCK SPLIT PROPOSAL | Board | For | — |
From Tenaya Therapeutics, Inc.’s Form 8-K, filed May 29, 2026, for the meeting held May 27, 2026 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Amy Burroughs, M.B.A. | 97% | Elected |
| Elect Director: Karah Parschauer, J.D. | 96% | Elected |
| Elect Director: Catherine Stehman-Breen, M.D. | 96% | Elected |
| 2. Ratification of the Appointment of Independent Registered Public Accounting Firm | 99% | Approved |
| 3. Approval of the Company's Amended and Restated 2021 Equity Incentive Plan | 77% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.